Table 1. Baseline characteristics of the patients.
| Group A | Group B | |
| (n = 242) | (n = 45) | |
| Male, no. (%) | 183 (75.6) | 34 (75.6) |
| Age, years, M (range) | 44 (21–81) | 42 (25–67) |
| Weight, kg, M (range) | 69 (45–139) | 67 (49–116) |
| Risk factor for HIV, no. (%) | ||
| Previous iv drug use | 80 (33.0) | 14 (31.1) |
| Hetero/homosexual | 154 (63.6) | 29 (64.4) |
| Other | 8 (3.3) | 2 (4.4) |
| Methadone treatment, no. (%) | 30 (12.3) | 8 (17.7) |
| Nadir CD4/µl, M (range) | 198 (4–762) | 218 (6–480) |
| Clinical category C, no. (%) | 57 (23.5) | 9 (20.0) |
| Chronic hepatitis/cirrhosis, no. (%) | 69 (28.5)/21 (8.6) | 8 (17.7)/5 (11.1) |
| HCV | 81 (90.0) | 9 (69.2) |
| HBV | 5 (5.5) | 1 (7.6) |
| HCV+HVB | − | 2 (14.3) |
| Other | 3 (3.3) | 2 (14.3) |
| No. previous ART, M (range) | 2 (1–9) | 2 (1–7) |
| Months on previous ART, M (range) | 36 (1–186) | 37 (3–168) |
| Previous antiretroviral regimen, no. (%) | ||
| EFV +2 NRTIs | 134 (55.3) | 38 (84.4) |
| NVP +2 NRTIs | 16 (6.6) | 7 (15.5) |
| IP/rtv +2 NRTIs | 87 (35.9) | − |
| 3 NRTIs | 5 (2.0) | − |
| Previous failure on NNRTIs, no. (%) | − | 45 (100) |
| Available genotypic resistance test, no. (%) | 137 (56.6) | 45 (100) |
| Wild type | 124 (90.5) | 17 (37.8) |
| K103N | − | 22 (48.9) |
| L100I or K101E or V179T | − | 3 (6.6) |
| G190A | − | 2 (4.4) |
| CD4/µl, M (range) | 473 (12–1360) | 468 (31–1351) |
| HIV-RNA copies/ml, M (range) | <50 (<50–444867) | 982 (108–170000) |
| HIV-RNA <50 copies/ml, no. (%) | 179 (74.0) | − |
| Associated NRTIs, no. (%) | ||
| TDF+FTC | 146 (60.3) | 22 (48.9) |
| ABV +3TC | 83 (34.3) | 9 (20.0) |
| AZT+TDF | 5 (2.1) | 10 (22.2) |
| ABV+TDF | 5 (2.1) | 2 (4.4) |
| AZT +3TC | 2 (0.8) | − |
| ddI +3TC | 1 (0.4) | 2 (4.4) |
| ETR 400 mg qd, no. (%) | 215 (88.8) | 29 (64.4) |
ART: antiretroviral treatment. NRTIs: nucleos(t)ide reverse-transcriptase inhibitors. NNRTIs: non-nucleoside reverse-transcriptase inhibitors. EFV: efavirenz. NVP: nevirapine. TDF: tenofovir. FTC: emtricitabine. ABV: abacavir. 3TC: lamivudine. AZT: zidovudine.